Product Description
Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19239399/)
Mechanisms of Action: DR Agonist, D2 Agonist, D3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Germany
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Parkinson's Disease|Sleep Apnea, Obstructive|Sleep Bruxism
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2025-521172-64-00 |
1462rot25ct | P2 |
Not yet recruiting |
Parkinson's Disease |
2025-12-15 |
|||
2019-001898-87 |
STRIVE | P2 |
Completed |
Sleep Apnea, Obstructive|Sleep Bruxism |
2023-10-28 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20221662 |
CTR20221662 | P1 |
Completed |
Parkinson's Disease |
2023-05-20 |
2025-04-29 |